Literature DB >> 1701391

Interleukin 4 down-regulates the expression of CD14 in normal human monocytes.

R P Lauener1, S M Goyert, R S Geha, D Vercelli.   

Abstract

Recombinant interleukin 4 (IL4) down-regulates the expression of CD14 on normal human monocytes, as assessed by flow cytometry, binding assays with radiolabeled anti-CD14 monoclonal antibody (mAb), and immunoprecipitation of 125I-labeled monocytes with anti-CD14 mAb. In parallel, CD23 expression on monocytes was strongly increased by IL4 stimulation, as assessed by both flow cytometry and immunoprecipitation. Down-regulation of surface CD14 was first detectable after 24-36 h of incubation with rIL4, and was almost complete after 4 days of culture. None of the other recombinant lymphokines tested (IL1, IL2, IL3, IL5, IL6, interferon-gamma, tumor necrosis factor alpha and beta, granulocyte-macrophage colony-stimulating factor) decreased CD14 expression. Metabolic labeling studies with [35S]methionine showed that both the membrane-associated and the soluble form of CD14 are decreased by IL4 stimulation. Northern blot analysis showed that incubation of monocytes with IL4 induced a marked decrease in CD14 mRNA. Nuclear run-off assays revealed that the IL4-dependent down-regulation of CD14 resulted from decreased transcription. Thus, IL4 exerts specific and opposite effects on the expression of monocytic antigens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701391     DOI: 10.1002/eji.1830201103

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression.

Authors:  A K Eckstein; B Quadbeck; S Tews; K Mann; C Krüger; C H Mohr; K-P Steuhl; J Esser; R K Gieseler
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  MUTZ-3, a monocytic model cell line for interleukin-4 and lipopolysaccharide studies.

Authors:  H Quentmeier; A Duschl; Z B Hu; B Schnarr; M Zaborski; H G Drexler
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  Role of leukotriene B4 in the interleukin-4-induced human mononuclear phagocyte activation.

Authors:  N Dugas; B Dugas; J P Kolb; K Yamaoka; J F Delfraiss; C Damais
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  Increased adhesion of human monocytes to IL-4-stimulated human venous endothelial cells via CD11/CD18, and very late antigen-4 (VLA-4)/vascular cell adhesion molecule-1 (VCAM-1)-dependent mechanisms.

Authors:  E M Verdegaal; H Beekhuizen; I Blokland; R van Furth
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

Review 5.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

Review 6.  Soluble CD14: role in atopic disease and recurrent infections, including otitis media.

Authors:  Karin C Lødrup Carlsen; Berit Granum
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

7.  The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism.

Authors:  M Ulanova; A Tarkowski; M Hahn-Zoric; L A Hanson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

8.  Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis.

Authors:  J Homolka; J Lorenz; H D Zuchold; J Müller-Quernheim
Journal:  Clin Investig       Date:  1992-10

9.  Biochemical and functional alterations induced by CD23 ligation in the human promonocytic cell line U937.

Authors:  N Paul-Eugene; C Amirand; F Ouaaz; J P Ballini; D M Mossalayi; B Dugas; J P Kolb
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

10.  CD14 and tolerance to lipopolysaccharide: biochemical and functional analysis.

Authors:  M O Labeta; J J Durieux; G Spagnoli; N Fernandez; J Wijdenes; R Herrmann
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.